* Three-Year follow-up phase 3 data provide additional
information
on efficacy, durability and safety of investigational
Luxturna(voretigene neparvovec) in patients with biallelic
RPE65-mediated inherited retinal disease
Source text for Eikon:
Further company coverage:

Read More At Article Source | Article Attribution